Fatal Fungal Peritonitis Caused by Aspergillus udagawae: An Autopsy Case Report.

Intern MedFeb 10, 2026 (epub)
Case ReportInfectious DiseasesGastroenterologyPathology (Anatomic & Clinical)

Kengo Nishino, Takumi Kiwamoto, Chio Sakai et al.

✦ AI-curated · Sources linked

Case in brief

A 56-year-old man with chronic progressive pulmonary aspergillosis caused by multidrug-resistant Aspergillus udagawae developed acute abdominal pain. Computed tomography showed a ruptured intra-abdominal abscess and ascites. He underwent emergency surgery for peritonitis but died on day 5. Autopsy revealed multiple fungal abscesses and showed direct invasion and hematogenous spread from the lungs to the peritoneum. Genetic analysis confirmed A. udagawae as the causative organism.

What made this case unusual

Autopsy established fatal fungal peritonitis from pulmonary A. udagawae infection, with both direct invasion and hematogenous spread to the peritoneum.

Diagnostic / clinical pearl

In treatment-refractory Aspergillus infection, molecular identification can clarify the causative species; in this case, genetic analysis confirmed A. udagawae.

Source

PubMed · PMID 41672531

Published in Intern Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.